Sheep anti-Human VWF / Von Willebrand Factor Polyclonal Antibody | anti-VWF antibody

Sheep Polyclonal (IgG) to Human VWF / Von Willebrand Factor

Cat. Num. AAA247436

• Gene Names: VWF; VWD; F8VWF
• Reactivity: Human
• Applications: Immunohistochemistry, Immunohistochemistry, Immunofluorescence
• Purity: Ion exchange Chromatography
• Synonyms: VWF / Von Willebrand Factor; Polyclonal Antibody; Sheep Polyclonal (IgG) to Human VWF / Von Willebrand Factor; Anti-VWF / Von Willebrand Factor Antibody (FITC) IHC-plus; VWF; Coagulation factor VIII VWF; F8VWF; VWD; Von Willebrand factor; Human VWF; Von Willebrand Factor; anti-VWF antibody

• Host: Sheep
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes human Von Willebrand Factor (vWF). No arcs when tested by IEP against human serum. Identity has been confirmed by double diffusion (Ouchterlony) vs. human vWF and an anti-human vWF of known specificity.
• Purity/Purification: Ion exchange Chromatography
• Form/Format: PBS, pH 7.2, 0.09% sodium azide.
• Sequence Length: 2813

• Applicable Applications for anti-VWF antibody: Immunohistochemistry (IHC - Paraffin, IHC - Frozen), Immunofluorescence (IF)
• Application Notes: IF (1:25 - 1:50), IHC-Fr, IHC-P (1:200); Usage: Suitable for use in Immunofluorescence. Immunofluorescence (Direct): 1:25-1:50 (frozen sections of human tonsil).
• Target Species: Human
• Immunogen Description: Human von Willebrand Factor Antigen (vWF) prepared from citrated human plasma (>95%).
• Immunogen: VWF / Von Willebrand Factor antibody was raised against human von Willebrand Factor Antigen (vWF) prepared from citrated human plasma (>95%).
• Antibody Modification: FITC
• Preparation and Storage: Short term 4 degree C, long term aliquot and store at -20 degree C, avoid freeze thaw cycles.

Immunohistochemistry (IHC)

(Anti-VWF antibody IHC of human spleen, endothelium. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.)

Related Product Information for anti-VWF antibody

Von Willebrand Factor (VWF) functions as both an antihemophilic factor carrier and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease.

NCBI and Uniprot Product Information

• NCBI GI #: 89191868
• NCBI GeneID: 7450
• NCBI Accession #: NP_000543.2
• NCBI GenBank Nucleotide #: NM_000552.3
• UniProt Accession #: P04275; Q8TCE8; Q99806
• Molecular Weight: 38,745 Da
• NCBI Official Full Name: von Willebrand factor preproprotein
• NCBI Official Synonym Full Names: von Willebrand factor
• NCBI Official Symbol: VWF
• NCBI Official Synonym Symbols: VWD; F8VWF
• NCBI Protein Information: von Willebrand factor; coagulation factor VIII VWF
• UniProt Protein Name: von Willebrand factor
• Protein Family: von Willebrand factor
• UniProt Gene Name: VWF
• UniProt Synonym Gene Names: F8VWF; vWF
• UniProt Entry Name: VWF_HUMAN

NCBI Description

The glycoprotein encoded by this gene functions as both an antihemophilic factor carrier and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease. An unprocessed pseudogene has been found on chromosome 22. [provided by RefSeq, Jul 2008]

Uniprot Description

VWF: Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Defects in VWF are the cause of von Willebrand disease type 1 (VWD1). A common hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 1 is characterized by partial quantitative deficiency of circulating von Willebrand factor, that is otherwise structurally and functionally normal. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 2 (VWD2). A hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 2 is characterized by qualitative deficiency and functional anomalies of von Willebrand factor. It is divided in different subtypes including 2A, 2B, 2M and 2N (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M are defective in their platelet- dependent function, whereas the mutant protein in type 2N is defective in its ability to bind factor VIII. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 3 (VWD3). A severe hemorrhagic disorder due to a total or near total absence of von Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. Bleeding usually starts in infancy and can include epistaxis, recurrent mucocutaneous bleeding, excessive bleeding after minor trauma, and hemarthroses.

Protein type: Motility/polarity/chemotaxis; Extracellular matrix; Secreted; Cell adhesion; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 12p13.3

Cellular Component: extracellular matrix; proteinaceous extracellular matrix; endoplasmic reticulum; extracellular region; external side of plasma membrane

Molecular Function: integrin binding; collagen binding; identical protein binding; protein binding; protein homodimerization activity; protease binding; chaperone binding; immunoglobulin binding; protein N-terminus binding; glycoprotein binding

Biological Process: platelet activation; extracellular matrix organization and biogenesis; platelet degranulation; hemostasis; response to wounding; cell adhesion; liver development; blood coagulation; blood coagulation, intrinsic pathway; cell-substrate adhesion; protein homooligomerization; placenta development

Disease: Von Willebrand Disease, Type 3; Von Willebrand Disease, Type 1; Von Willebrand Disease, Type 2